secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001564590-22-020233
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%
--------------------------------------------------------------------------------

- Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.
- GPH102 aims to replace mutated beta-globin gene to treat beta-thalassemia, targeting IND submission by mid-2024.
- Encore poster for GPH101 Phase 1/2 CEDAR trial for sickle cell disease also presented at ASGCT.
- Data accepted for encore presentation at EHA 2022 Hybrid Congress in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/0001564590-22-020233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/grph-8k_20220516.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-020233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer